Project

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA

Ongoing - recruitment closed · 2023 until 2026

Huober Jens, Quinter Janine, Kehl Jeanine